Louis Mauriac1, Gilles Romieu, José Bines. 1. Institut Bergonié, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, France. mauriac@bergonie.org
Abstract
PURPOSE:Patients with visceral metastases (VM: lung and/or liver metastases) are generally regarded as being less responsive to hormonal therapy, and chemotherapy often becomes the default treatment. This paper reports a subgroup analysis from EFECT (The Evaluation of Faslodex versus Exemestane Clinical Trial) examining the efficacy of fulvestrant and exemestane in patients with or without VM. METHODS:EFECT is a randomised, double-blind, multicentre, Phase III trial in postmenopausal women with advanced breast cancer progressing or recurring after prior non-steroidal aromatase inhibitor therapy. RESULTS: Overall, approximately 57% of patients in EFECT had visceral involvement. Fulvestrant and exemestane demonstrated clinical benefit in 29.1% and 27.2% of patients with VM, respectively. Median duration of response was 13.5 vs 10.8 months and median duration of clinical benefit was 9.9 vs 8.1 months, respectively. CONCLUSIONS: These results encourage the use of endocrine agents such as fulvestrant in treating patients with advanced breast cancer and VM.
RCT Entities:
PURPOSE:Patients with visceral metastases (VM: lung and/or liver metastases) are generally regarded as being less responsive to hormonal therapy, and chemotherapy often becomes the default treatment. This paper reports a subgroup analysis from EFECT (The Evaluation of Faslodex versus Exemestane Clinical Trial) examining the efficacy of fulvestrant and exemestane in patients with or without VM. METHODS: EFECT is a randomised, double-blind, multicentre, Phase III trial in postmenopausal women with advanced breast cancer progressing or recurring after prior non-steroidal aromatase inhibitor therapy. RESULTS: Overall, approximately 57% of patients in EFECT had visceral involvement. Fulvestrant and exemestane demonstrated clinical benefit in 29.1% and 27.2% of patients with VM, respectively. Median duration of response was 13.5 vs 10.8 months and median duration of clinical benefit was 9.9 vs 8.1 months, respectively. CONCLUSIONS: These results encourage the use of endocrine agents such as fulvestrant in treating patients with advanced breast cancer and VM.
Authors: I Blancas; M Fontanillas; V Conde; J Lao; E Martínez; M J Sotelo; A Jaen; J L Bayo; F Carabantes; J J Illarramendi; M M Gordon; J Cruz; A García-Palomo; C Mendiola; E Pérez-Ruiz; J S Bofill; J M Baena-Cañada; N M Jáñez; G Esquerdo; M Ruiz-Borrego Journal: Clin Transl Oncol Date: 2017-11-24 Impact factor: 3.405